Previous 10 | Next 10 |
2023-03-16 10:03:57 ET Gainers: Lipella Pharmaceuticals ( LIPO ) +48% . ThermoGenesis Holdings ( THMO ) +34% . Genelux ( GNLX ) +14% . Homology Medicines ( FIXX ) +10% . Biora Therapeutics ( BIOR ) +7% . Losers: Esperi...
2023-03-16 09:10:41 ET Esperion Therapeutics ESPR -58% in dustup with Daiichi Sankyo over milestone payments . LivePerson LPSN -38% on Q4 earnings release . Virgin Orbit VORB -37% on reports it's pausing operations as it seeks funding . First Republ...
2023-03-16 09:07:22 ET Esperion Therapeutics ( NASDAQ: ESPR ) continued the post-market selloff on Thursday due to a payment dispute with Daiichi Sankyo ( OTCPK:DSNKY ) over its cholesterol-lowering agent bempedoic acid, prompting Bank of America to downgrade the stock. ...
2023-03-15 17:31:04 ET Esperion Therpeutics ( NASDAQ: ESPR ) has plummeted 55% in after-hours trading after disclosing that Daiichi Sankyo Europe ( OTCPK:DSNKY ) disagrees it owes the company milestone payments for its two cholesterol-lowering drugs containing bempedoic ...
– International Lipid Expert Group Recommends Earlier Utilization of Bempedoic Acid in Both Secondary Prevention Patients As Well As in Patients with Partial or Complete Statin Intolerance – – Following the “Lower Is Better For Longer” App...
2023-03-07 13:35:14 ET Credit Suisse raised its recommendation on anti-cholesterol treatment developer Esperion Therapeutics ( NASDAQ: ESPR ) despite its Monday's selloff following a Phase 3 readout for its heart disease therapy Nexletol. Esperion ( ESPR ) shares lost ~2...
2023-03-06 13:05:55 ET Gainers: Bellerophon ( BLPH ) +86% . Ambrx Biopharma ( AMAM ) +69% . BridgeBio Pharma ( BBIO ) +56% . Avalon GloboCare ( ALBT ) +47% . Azul ( AZUL ) +42% . TCR2 Therapeutics ( TCRR ) +38% . ...
2023-03-06 10:00:19 ET Gainers: BridgeBio Pharma ( BBIO ) +67% . Armata Pharmaceuticals ( ARMP ) +23% . TCR2 Therapeutics ( TCRR ) +21% . Euda Health ( EUDA ) +12% . Kala Pharmaceuticals ( KALA ) +16% . Losers: Aclaris...
2023-03-06 08:17:23 ET Aclaris Therapeutics ( ACRS ) -38% after preliminary topline data from 12-week Phase 2a study did not meet primary or secondary efficacy endpoints in hidradenitis suppurativa . Esperion Therapeutics ( ESPR ) -27% amid Nexletol data ...
2023-03-06 06:28:05 ET Esperion ( NASDAQ: ESPR ) reported detailed results from a phase 3 trial showing that Nexletol reduced risk of major adverse cardiovascular events (MACE-4). The company had previously reported data from the landmark Cholesterol Lowering via Be...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...